v3.26.1
Note 17 - Net Loss per Share
12 Months Ended
Dec. 31, 2025
Notes to Financial Statements  
Earnings Per Share [Text Block]

17.

Net Loss per Share

 

The Company applies the two-class method pursuant to the issuance of our Series B and Series C Preferred Stock. Accordingly, the Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Net loss attributable to common stockholders is equal to the Company’s net loss.

 

Diluted earnings per share are calculated using the more dilutive of the two-class or if-converted methods. The two-class method uses net income available to common stockholders and assumes conversion of all potential shares other than the participating securities. The if-converted method uses net income and assumes conversion of all potential shares including the participating securities. For the periods where a net loss attributable to common stockholders is present, dilutive securities have been excluded from the calculation of diluted net loss per share attributable to common stockholders as including them would have been anti-dilutive.

 

  

For the Year Ended December 31,

 
  

2025

  

2024

 

(In thousands, except per share amounts)

        

Net loss attributed to Tivic Health Systems, Inc.

 $(8,878) $(5,655)

Dividends on Series B Preferred Stock

  (120)  - 

Dividends on Series C Preferred Stock

  (48)  - 

Deemed dividends on warrants

  (10)  - 

Net loss attributed to Tivic Health Systems, Inc.

 $(9,056) $(5,655)

Basic and diluted weighted average number of shares outstanding

  1,155,531   287,370 

Net loss per share - basic and diluted

  (7.84)  (19.68)

 

The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:

 

  

For the Year Ended December 31,

 
  

2025

  

2024

 

Warrants to purchase common stock

  8,513,550   707,234 

Common stock options issued and outstanding

  392,494   8,868 

Restricted stock units issued and outstanding

  50,736    

Series A Preferred Stock

  237,200    

Series B Preferred Stock

  1,610,180    

Series C Preferred Stock

  9,371,123    

Total

  20,175,283   716,102